New appointments strengthen AI drug discovery software operations 

Optibrium, a software and artificial intelligence (AI) solutions developer for drug discovery, has announced three appointments: Michelle Harrison as Head of Strategic Marketing, Chris Khoury as Associate Director of Business Development, and Imran Ghauri as Business Development Manager.  

The company says the appointments will bring extensive AI and life science expertise and will align global business development and marketing strategies to further develop and commercialise Optibrium’s computer-aided drug discovery technologies.  

More than 170 organisations worldwide, including five of the top 10 global pharmaceutical companies, currently deploy Optibrium’s computational drug discovery technologies in their research programmes. Cerella, Optibrium’s proven AI platform, empowers project teams with valuable insights from complex drug discovery data to maximise the success of preclinical discovery projects. 

Dr Matthew Segall, CEO of Optibrium, said: “As part of our continuing expansion and commercial success, we are delighted to welcome Michelle, Chris and Imran to the Optibrium team. Their impressive backgrounds in scientific marketing strategy and business development will power the next phase of our development and further strengthen the position of our market-leading in silico technologies and AI platforms.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free